查找临床试验
已按「系统性硬化症」检索，对应国际通用词 systemic sclerosis
共找到 12 项正在招募的试验（在中国／港澳台设有中心）
数据更新于 11:24，每 5 分钟自动同步Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
China
年龄 18 Years – 70 Years
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
China
年龄 18 Years – 70 Years
Changhai Hospital
Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
China
年龄 18 Years – 65 Years
Second Affiliated Hospital, Zhejiang University, School of Medicine
the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases
China
年龄 18 Years – 65 Years
Tongji Hospital
A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
China
年龄 18 Years – 65 Years
Therorna
CAR-T Cells Therapy for Patients With Autoimmune Diseases
China
年龄 18 Years – 不限
Anhui Provincial Hospital
A Study of CC312 for Relapsed/Refractory Autoimmune Diseases
China
年龄 18 Years – 65 Years
CytoCares Inc
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
China
年龄 18 Years – 90 Years
Essen Biotech
Relmacabtagene Autoleucel for the Treatment of Systemic Sclerosis
China
年龄 18 Years – 65 Years
Liangjing Lu
Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
China
年龄 3 Years – 不限
The Children's Hospital of Zhejiang University School of Medicine
Safety Study of CC312 in Autoimmune Disease Patients
China
年龄 18 Years – 不限
CytoCares Inc
Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSC
China
年龄 18 Years – 60 Years
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology